AUTHORS
Amrita Krishnan, MD, FACP, Bradley Augustson2, Sridevi Rajeeve, MD3, Sueh-Li Lim, MBBS FRACP FRCPA4, Hira S Mian5, Cyrille Touzeau Sr, MD, PhD6, Clifton C. Mo, MD7, Shinsuke Iida, PhD8, Matthew J. Pianko, MD9, Katja Weisel, MD10, Junichiro Yuda, MD, PhD11, Stefan Knop12, Maria-Victoria Mateos Jr, MD, PhD13, Eva Catalá14, Marco Salvino15, Patricia Pak Yan Cheung, PhD16, Claire Miller17, Jamal Saeh18, Nina Shah, MD19, Edward A. Stadtmauer, MD20
AFFILIATIONS
1 City of Hope Comprehensive Cancer Center, Duarte, California, United States
2 Sir Charles Gairdner Hospital and Linear Clinical Research, Perth, Australia
3 David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Alfred Health, Melbourne, Australia
5 Juravinski Cancer Centre, Hamilton, Ontario, Canada
6 Centre Hospitalier Universitaire de Nantes, Nantes, France
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
9 University of Michigan, Ann Arbor, Michigan, United States
10 Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
11 National Cancer Center Hospital East, Kashiwa, Japan
12 Klinikum Nürnberg Campus Nord, Nuremberg, Germany
13 Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca-Consejo Superior de Investigaciones Científicas), Centro de Investigación Biomédica en Red de Cáncer,, Salamanca, Spain
14 Haematology Research & Development, AstraZeneca, Waltham, Massachusetts, United States
15 Haematology, AstraZeneca, Barcelona, Spain
16 Translational Medicine, Haematology, AstraZeneca, South San Francisco, California, United States
17 Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Cambridge, United Kingdom
18 Haematology Research & Development, AstraZeneca, Waltham, Massachusetts, United States
19 Multiple Myeloma Clinical Development and Strategy, AstraZeneca, South San Francisco, California, United States
20 University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction: G protein–coupled receptor, class C, group 5, member D (GPRC5D) has been established as a therapeutic target for multiple myeloma (MM). Talquetamab, a bispecific GPRC5D-directed T-cell engager, is approved for adults with relapsed or refractory MM (RRMM) who have received multiple prior lines of therapy (pLOT). However, an unmet need remains for therapeutic approaches with acceptable safety and tolerability profiles without reliance on T cells. Vemzatatug vedotin (Vemza-Ve, AZD0305) is a first-in-class antibody-drug conjugate (ADC) that binds specifically to GPRC5D and incorporates monomethyl auristatin E as a payload. Here, we report for the first time the safety and preliminary efficacy of Vemza-Ve from a first-in-human dose-escalation study in RRMM.
Methods: Vemza-Ve was evaluated in a phase 1/2, open-label, multicenter study (NCT06106945). Eligible patients were aged ≥18 years with documented MM, ECOG performance status 0–2, and prior exposure to ≥3 pLOT including a proteasome inhibitor, immunomodulatory drug (IMiD), and anti-CD38 antibody. Dose escalation evaluated 8 dose levels (DLs; 0.2–3.2 mg/kg) administered intravenously once every 21 days using a 3+3 dose-escalation design. Primary objectives were to assess safety/tolerability and determine the recommended phase 2 dose (RP2D). Secondary objectives included evaluation of preliminary efficacy. Safety outcomes included adverse events (AEs) graded by CTCAE v5.0 and dose-limiting toxicities (DLTs). Efficacy was assessed using International Myeloma Working Group (IMWG) 2016 response criteria.
Results: As of data cutoff on May 6, 2026, 88 participants received Vemza-Ve (DL1–4 [0.2–1.6 mg/kg], n=3 each; intermediate DL [2.0 mg/kg], n=12; DL5–6 [2.4 and 2.8 mg/kg], n=26 each; DL7 [3.2 mg/kg], n=12). Median age was 69 years (range, 37–88), median pLOT was 6 (range, 3–17), 65% of participants were triple-class refractory to proteasome inhibitors, IMiDs, and anti-CD38 antibodies, 77% had prior anti-BCMA therapy (51% with prior BCMA-directed T-cell–engager therapy, 16% with prior ADC therapy), 55% had high-risk cytogenetic features, and 41% had extramedullary disease. Median duration of Vemza-Ve exposure was 1.7 months (range, 1–15). DLTs of grade (G) 3 febrile neutropenia (n=1, 2.4 mg/kg), G3 nausea (n=1, 2.8 mg/kg), and G4 pneumonia aspiration (n=1, 3.2 mg/kg) were observed. The maximum tolerated dose (MTD) was not reached and the RP2D was determined to be 2.4 mg/kg by the Safety Review Committee based on safety and efficacy data across all dose levels evaluated. The most common AEs of any grade observed at 2.4 mg/kg were neutrophil count decreased (62%), diarrhea (39%), peripheral sensory neuropathy (39%), fatigue (35%), nausea (35%), and alopecia (35%); the most common G≥3 AEs were anemia (15%), white blood cell count decreased (15%), back pain (8%), fatigue (8%), and platelet count decreased (8%). AEs at 2.4 mg/kg potentially associated with the GPRC5D target included weight loss (15%), dry mouth (8%), and dysgeusia (8%) (all G≤2); no nail disorder events were reported. There were no G3–4 neuropathy events. There was 1 G2 keratopathy event, which was deemed not related to Vemza-Ve. Five participants (19%) discontinued treatment due to neuropathy. No AE-related deaths occurred during treatment. At 2.4 mg/kg, the overall response rate (ORR) was 31% (8/26; CR, 4% [n=1]; very good partial response, 12% [n=3]; partial response, 15% [n=4]), with 1 participant achieving MRD negativity by next-generation sequencing (sensitivity, 10-6). Median duration of response was 12.7 months (95% confidence interval, 4.4 to not reached). At 2.4 mg/kg, the ORR in participants with prior anti-BCMA therapy was 39% (7/18); ORR was higher in those with prior BCMA-directed T-cell–engager therapy (60% [6/10]). While no responses were observed at 0.2–2.0 mg/kg, transient decreases in free light chain levels were observed at 2.0 mg/kg; ORRs at 2.8 mg/kg and 3.2 mg/kg were 8% (2/26) and 17% (2/12), respectively.
Conclusion: Vemza-Ve is a first-in-class GPRC5D-targeting ADC. In this phase 1 dose escalation study, the MTD was not reached. The RP2D of 2.4 mg/kg was well tolerated with manageable AEs and limited GPRC5D-associated toxicity and was associated with encouraging preliminary efficacy in a heavily pretreated patient population, including those with prior anti-BCMA exposure and prior BCMA-directed T-cell–engager therapy. Phase 1 combination studies are underway (NCT06106945).
DISCLOSURES
Amrita Krishnan, MD, FACP: Bristol Meyers-Squibb - Stock (publicly traded); Legend Pfizer - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Bristol Meyers-Squibb - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony)